Background Acute kidney injury (AKI) is a common complication of cardiopulmonary bypass surgery (CPB) in children. Several promising postoperative AKI biomarkers have been identified, but no preoperative biomarkers are available. We evaluated the association of urinary uromodulin (uUMOD) with postoperative AKI. Methods One hundred and one children undergoing CPB were enrolled. Urine was collected prior to CPB, and AKI was defined as ≧50% increase in serum creatinine from preoperative baseline within 48 h of surgery. Results Forty-seven patients (47%) developed AKI, and 92% of participants in the lowest quartile of preoperative uUMOD concentrations developed AKI compared with 8% in the highest quartile. Patients with preoperative uUMOD levels in the lowest quartile had 132.3× increased risk of postoperative AKI versus the highest quartile. Raw uUMOD levels were significantly lower in patients with AKI vs. no AKI. Significance was unchanged after correcting uUMOD levels for urinary creatinine. Receiver operating characteristic analysis showed preoperative uUMOD strongly predicted postoperative AKI, with area under the curve (AUC) 0.90. Stepwise logistic regression analysis revealed a model combining uUMOD, and bypass time predicted AKI at p<0.001. Neither Risk Adjustment for Congenital Heart Surgery 1 (RACHS) score nor age improved the model's ability to predict AKI. Independent analysis demonstrated that while bypass time was associated with AKI, the predictive ability of bypass time (AUC 0.77) was less than that of preoperative uUMOD levels (AUC 0.9). Conclusions Children with lowest preoperative levels of uUMOD have greatly increased risk of AKI post-CPB. If uUMOD were used to risk-stratify patients undergoing CPB, clinical measures could be taken to minimize AKI development.
Introduction
Acute kidney injury (AKI) is a common and serious complication of cardiopulmonary bypass surgery (CPB), occurring in up to 50% of pediatric patients undergoing the procedure [1, 2] . Depending on the definition of AKI used, the mortality rate ranges between 20 and 79% [1, 3] . Risk factors for AKI after CPB include age <2 years, history of prior surgeries, and longer bypass time [1, 4, 5] .
Much research has been dedicated to the discovery of postoperative biomarkers to predict AKI and its severity. Proteins that mark tubular damage, such as neutrophil gelatinaseassociated lipocalin (NGAL), interleukin 18 (IL-18), and kidney injury molecule-1, have shown promise as potential early diagnostic indicators of AKI [6] [7] [8] [9] [10] [11] . However, there are currently no preoperative measures in use to determine a patient's predisposition to developing AKI after CPB. Recent studies have demonstrated that lower urinary excretion of uromodulin (UMOD), also known as Tamm-Horsfall Protein (THP), measured in adult patients prior to CPB is associated with higher odds of developing AKI postsurgery [12] .
UMOD is the most abundant protein excreted in urine. It is a glycoprotein that is expressed in the thick ascending limb (TAL) of the loop of Henle and was first purified by Igor Tamm and Frank Horsfall in 1952 [13] [14] [15] . Mutations in the UMOD gene are associated with medullary cystic kidney disease and autosomal dominant tubulointerstitial kidney disease [16, 17] . In healthy kidneys, UMOD is thought to have a role in salt transport in the tubules, innate immunity, and protection against kidney stones [18] .
In this study, we aimed to determine whether preoperative levels of urinary UMOD (uUMOD) are associated with risk of AKI in a cohort of pediatric patients undergoing CPB.
Patients and methods
Patients with pre-existing renal insufficiency lserum creatinine ( S Cr) >2× age-adjusted normal range] were excluded. Past nephrotoxin use, such as contrast or aminoglycoside, was not an exclusion factor as long as the S Cr was normal at the time of surgery. Complexity of surgery was categorized according to the Risk Adjustment for Congenital Heart Surgery 1 (RACHS-1) scoring system [19] . Urine samples for biomarker analysis were obtained immediately before CPB and stored in aliquots at −80°C. S Cr was measured at baseline, immediately after surgery, and at least daily in the postoperative period.
The primary outcome measure was AKI, defined as a ≥50% increase in S Cr above preprocedural baseline within 48-h postsurgery, comprising modified Kidney Diesease: Improving Global Outcomes (KDIGO) criteria [20] . Secondary outcomes were bypass time and length of hospital stay.
Biomarker measurements
Urinary UMOD was measured using a clinically available enzyme-linked immunosorbent assay (ELISA) kit per manufacturer's instructions (EHUMOD, Thermo-Fisher Scientific, Waltham, MA, USA). Intra-and interassay variability were 10 and 12%, respectively. Urine Cr ( U Cr) was measured using an enzymatic Cr assay on a Dimension RXL clinical analyzer (Siemens, Munich, Germany). Coefficients of variability for Cr measurements were 2.4% (intra) and 4.2% (total).
Statistics
Statistical analysis was performed using SigmaPlot 12.5 (Systat Software, Inc., Chicago, IL, USA). Demographics, baseline measurements, and clinical outcomes were summarized and compared between patients with and without AKI. For continuous variables, median and interquartile ranges (IQR) were reported, and Wilcoxon rank-sum test was used to test for group differences. For categorical variables, frequencies and proportions were reported, and chi-square or Fisher's exact test was used for group differences. For UMOD measurements, median and IQR were calculated and subjected to Mann-Whitney rank-sum analysis. UMOD IQR was used to categorize patients into quartiles to calculate odds ratios (ORs) for the development of AKI. To determine association of clinical variables and UMOD levels with AKI, a stepwise logistic regression analysis was performed. Independent receiver operator characteristic curves (ROC) were calculated for each variable (UMOD, length of stay, RACHS score, and bypass time), and area under the curve (AUC) was calculated to determine the discriminatory power for each variable to predict AKI. In all tests, p values ≤0.05 were considered significant.
Results

Patient characteristics
One hundred and one patients <18 years undergoing on-pump cardiac surgery at our center were enrolled in this prospective study. Forty-seven (47%) developed AKI. Patient demographic and clinical characteristics can be found in Table 1 . There were no differences between AKI and non-AKI patients in terms of age, sex, race, prior CPB, or RACHS score. Bypass times and length of hospital stay were significantly increased in AKI patients (p <0.001).
uUMOD and AKI Table 2 shows that 92% of participants in the lowest quartile of urinary UMOD levels developed AKI, compared with 8% in the highest quartile. ORs demonstrated that having a uUMOD level in the lowest quartile yielded a 132.3× increased risk of developing AKI vs. the highest quartile. Raw UMOD levels were significantly lower in patients with AKI (4.739 μg/ml; 25th 2.454; 75th 6.483) vs. no AKI (13.701 μg/ ml; 9.022, 20.999) (Fig. 1a) . Significance did not change with U Cr correction (Fig. 1b) . ROC analysis of preoperative uUMOD levels demonstrated an AUC of 0.90 for prediction of AKI (p<0.001) (Fig. 2) . Stepwise logistic regression analysis revealed that a model combining UMOD (F statistic 33) and bypass time (F statistic 32) could predict AKI with a p<0.001. Neither RACHS (F statistic 2.1, p = 0.15) or age (F statistic 1.6, p = 0.2) added to the ability of the model to predict AKI. Independent analysis demonstrated that while bypass time was associated with AKI, the predictive ability of bypass time AUC (0.77) was less than that of the preoperative uUMOD levels (AUC 0.90) (Fig. 2) .
uUMOD and nonrenal outcomes
Lower preoperative concentrations of uUMOD were also associated with a longer length of hospital stay (r = -0.31, p = 0.002) (Fig. 3) .
Discussion
This is the first study to show that lower preoperative levels of uUMOD in children undergoing CBP is associated with increased risk of AKI. We found that raw UMOD levels were significantly lower at baseline (p <0.001) in patients who developed AKI after CPB than those who did not. In fact, patients in the lowest quartile of baseline UMOD concentrations had a 132.5× increased odds of developing AKI postsurgery than those patients in the highest quartile. While increased bypass time was also associated with AKI (AUC 0.77), baseline uUMOD levels were more predictive of AKI (AUC = 0.90), independent of complexity of surgery or age. Baseline uUMOD levels were negatively associated with the length of hospital stay, likely due to increased incidence of AKI in patients with low baseline levels.
AKI is a common and serious complication of CPB in both children and adults. It occurs at a high rate in children (20-60%) and is associated with higher in-hospital mortality and increased length of stay [1, 20, 21] . Due to complications associated with AKI, it is also associated with a significant financial burden. In the United States, it is estimated that AKI accounts for increased hospitalization costs of US$5.4 -24 billion annually [22] . In the adult population, AKI after CPB is associated with increased risk of chronic kidney disease (CKD) and hypertension [23, 24] . In the pediatric population, higher incidences of CKD and hypertension at 5 years following CPB have been identified [21] .
UMOD production is restricted to the TAL of the loop of Henle and the most proximal portion of the distal tubule [25] . UMOD is a glycoprotein with the capability of binding to a large number of ligands [26] ; it binds to cells, immunoglobulins, cytokines, crystals, and ions. One proposed physiological role for UMOD is to bind harmful products to remove them from the tubular fluid [27] . UMOD is typically associated with the apical membrane domain of the TAL but has been shown in mice to translocate to the basolateral domain of the TAL, the interstitium, and the S3 segment of proximal tubules in the recovery period post-AKI [28] . This was hypothesized to contribute to potential cross-talk between the TAL and the S3 segment to downregulate inflammatory molecules in proximal tubules. The authors demonstrated that in a mouse model of ischemia reperfusion injury, the S3 tubular cells in UMODdeficient mice expressed a high level of macrophage inflammatory protein (MIP-2)-a neutrophil-attracting chemokine-and were surrounded by neutrophils. It is thought that the basolateral translocation of UMOD interacts with the S3 segments to reduce expression of MIP-2 and therefore decrease damage due to inflammation in the tubules [29] . Our data is consistent with earlier studies in both adult and neonate mice. Garimella et al. [12] found that lower presurgery levels of uUMOD in adults undergoing on-pump cardiac surgery had increased odds of AKI, but the significance of data in their population was not as strong as ours, and were more evident in cases of severe AKI. They also demonstrated that lower presurgery uUMOD was inversely related to peak S Cr postsurgery. This is consistent with the idea that UMOD has a protective effect on renal tubules. The slight differences in our results could be due to a number of variables. First, children have fewer comorbid conditions than adult patients, subjecting their biomarkers to fewer confounding variables. Second, the ELISA kit used by Garimella et al. [12] was discontinued by the manufacturer, necessitating a different kit for our analysis. Similarly, Askenazi et al. [30] demonstrated 62% lower levels of uUMOD in critically ill neonates with AKI than in those without. In this setting, it was not predictive, since the children already had AKI, but it did have a good discriminatory value (AUC 0.77) to distinguish AKI from non-AKI patients.
Our study has several strengths. We used a wellcharacterized patient cohort, which was useful in evaluating the predictive value of tubular markers to predict AKI postsurgery [9] . While we used a different commercially available ELISA kit than used in previous studies [12, 31] , results correlated well with the referenced kit (data not shown). To our knowledge, this is the first study to assess preoperative levels of uUMOD to determine AKI risk in pediatric patients undergoing CPB. Our results were consistent with adult studies but had a much higher degree of significance (p=0.03 in adults vs 0.001 in our study) [12] . We also determined that the association of uUMOD with AKI (AUC = 0.90) was independent of age, RACHS score, or bypass time.
Our study is not without limitations. This was a singlecenter study with a relatively small sample size. As such, we were unable to stratify patients by AKI severity. Stratification of AKI by pediatric-modified Risk, Injury, Failure, Loss, and End-stage kidney disease (pRIFLE) criteria, for instance, could be informative to determine whether there is a direct correlation between uUMOD levels and AKI severity. Lastly, our samples were stored at −80°C for 10 years at the time of our analysis. Studies show that storing urine for >8 months does yield a small, but significant decrease in uromodulin as measured by ELISA [32] , but there is no reason to expect that this decrease would be influenced differentially in samples from patients with AKI vs their non-AKI counterparts.
In conclusion, assessment of risk factors prior to CPB in children, including uUMOD levels, could allow physicians to implement strategies to reduce AKI risk and improve their overall outcomes. While this concept needs further exploration in a larger multicenter cohort to allow further validation and stratification for AKI severity, combining preoperative risk assessment with postoperative monitoring of tubular damage markers, such as NGAL, could yield significant improvement in the care of CPB patients.
